Psychological StressNFHSTNCT07622589
NeuroFinance Human Stress Trial During Financial and Informational Volatility
An observational study of Psychological Stress and Anxiety, run by Truway Health, Inc. at 1 site in United States.
Trial summary
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Psychological Stress, Anxiety, Emotional Stress
- What is being tested?
- Wearable Physiologic Monitoring Platform
- Type of treatment
- Medical device
- How many people
- 2,500 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jul 2026to 30 Jun 2029
- How long will I take part?
- 24 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of adult participants exposed to varying levels of financial market activity, economic stress environments, occupational stress, and digital media exposure. Participants may include retail investors, financial professionals, active traders, technology workers, digitally connected individuals, and members of the general population. The study is designed to evaluate physiologic, behavioral, cardiovascular, autonomic nervous system, and sleep-related responses to financial and informational stress environments using wearable biosensors, digital health technologies, and artificial intelligence-assisted analytics platforms.
Who may be able to join
- Adults age 18 years and older.
- Ability to provide informed consent.
- Willingness and ability to comply with study procedures and remote monitoring requirements.
- Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.
- Willingness to utilize wearable physiologic monitoring technologies during the study period.
- Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible.
- Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled.
- Ability to read and understand English-language consent and study materials.
Who cannot join
- Individuals unable or unwilling to provide informed consent.
- Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.
- Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.
- Current incarceration or institutionalization limiting voluntary participation.
- Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes.
- Any condition that would significantly impair safe study participation as determined by the study investigators.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
Read the detailed description
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a prospective, decentralized observational study designed to evaluate physiologic and behavioral responses associated with exposure to financial market volatility, economic uncertainty, and digitally mediated informational stress environments.
Participants will undergo remote monitoring using commercially available wearable biosensor technologies and digital health platforms. Data collection may include continuous or intermittent monitoring of:
Heart rate variability (HRV) Resting heart rate Sleep duration and sleep efficiency Blood pressure measurements Physical activity metrics Galvanic skin response Voice-based behavioral analytics Optional electrocardiographic monitoring
Environmental and informational exposure datasets may include:
Financial market volatility indices News sentiment datasets Social media exposure metrics Economic uncertainty indicators Behavioral interaction telemetry
Artificial intelligence and machine learning systems may be used for exploratory correlation analyses between physiologic biomarkers and external informational stressors.
No investigational drug or invasive intervention will be administered as part of this observational study.
Optional biologic sampling may include saliva-based inflammatory biomarker collection and participant-reported psychometric assessments.
Primary analyses will evaluate longitudinal changes in physiologic stress-related biomarkers during periods of elevated informational or financial stress exposure.
Secondary analyses will evaluate associations between physiologic variability, behavioral adaptation metrics, sleep disruption, and cognitive performance measures.
The study is intended to support development of digital biomarker methodologies and decentralized monitoring frameworks for stress-related physiologic research.
- Conditions
- Psychological Stress, Anxiety, Emotional Stress, Autonomic Nervous System Dysfunction, Sleep Disturbance, Insomnia
- Being tested
- Wearable Physiologic Monitoring Platform
- Keywords
- NeuroFinance, Financial Stress Medicine, Wearable Biosensors, Artificial Intelligence, Machine Learning, Digital Biomarkers, Heart Rate Variability, Sleep Monitoring, Behavioral Analytics, Cardiovascular Telemetry, Decentralized Clinical Trial, Emotional Resilience, Physiologic Stress, Market Volatility, Economic Uncertainty, Social Media Exposure, Cognitive Performance, Stress Forecasting, Precision Wellness, Remote Patient Monitoring
- Medical subject headings
- Stress, Psychological, Anxiety Disorders, Parasomnias, Sleep Initiation and Maintenance Disorders, Occupational Stress, Financial Stress, Burnout, Psychological, Neurobehavioral Manifestations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wearable Physiologic Monitoring PlatformDevice
Commercially available wearable physiologic monitoring devices and digital health technologies will be used to collect continuous or intermittent biometric, cardiovascular, autonomic nervous system, behavioral, and sleep-related data during exposure to financial market volatility, economic uncertainty, and information-driven stress environments.
Monitoring technologies may include:
wearable ECG devices, heart rate variability (HRV) monitors, blood pressure monitoring systems, sleep tracking devices, galvanic skin response sensors, activity monitoring wearables, voice analysis systems, and optional EEG-enabled wearable technologies.
Data generated from these systems will be integrated with artificial intelligence and machine learning-based analytics platforms for evaluation of physiologic stress responses and digital biomarker forecasting.
| Study group | Role | What they receive |
|---|---|---|
| Retail Investors / Active Traders Cohort | Participants actively engaged in retail equity, options, futures, cryptocurrency, or other financial trading activities who are exposed to frequent market volatility and information-driven financial stress environments. Receives: Device: Wearable Physiologic Monitoring Platform | |
| Financial Professionals Cohort | Participants employed in financial services, institutional trading, investment banking, hedge funds, private equity, fintech, wealth management, or related high-stress financial occupations. Receives: Device: Wearable Physiologic Monitoring Platform | |
| General Population Control Cohort | Participants from the general population with varying levels of financial market exposure serving as a comparative baseline cohort for physiologic and behavioral stress-response analysis. Receives: Device: Wearable Physiologic Monitoring Platform | |
| High Digital Media Exposure Cohort | Participants with elevated exposure to financial news, algorithmic media feeds, social media platforms, and information-intensive digital environments associated with financial and geopolitical stress signaling. Receives: Device: Wearable Physiologic Monitoring Platform |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Heart Rate Variability (HRV) During Financial Stress Exposure
Heart rate variability will be measured using wearable electrocardiographic or photoplethysmographic monitoring devices. HRV will be quantified as the root mean square of successive differences (RMSSD) in milliseconds. Higher RMSSD values generally indicate improved autonomic nervous system flexibility and lower physiologic stress burden.
Measured: Baseline through 24 Months
Change in Sleep Duration
Sleep duration will be measured in hours per night using wearable sleep monitoring devices.
Measured: Baseline through 24 Months
Change in Resting Heart Rate
Resting heart rate will be measured in beats per minute using wearable biosensor devices.
Measured: Baseline through 24 Months
Change in Perceived Stress Scale-10 (PSS-10) Total Score
Perceived stress will be assessed using the validated 10-item Perceived Stress Scale-10 questionnaire. Scores range from 0 to 40, with higher scores indicating greater perceived psychological stress and worse stress-related outcomes.
Measured: Baseline through 24 Months
Secondary outcomes (3)
Change in Sleep Efficiency
Sleep efficiency percentage measured using wearable sleep tracking systems.
Measured: Baseline through 24 Months
Change in Galvanic Skin Response (GSR) Measurements
Electrodermal activity will be measured in microsiemens using wearable biosensor devices to assess sympathetic nervous system activation and physiologic stress responsiveness. Higher values may reflect increased autonomic arousal during stress exposure conditions.
Measured: Baseline through 24 Months
Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score
Anxiety symptoms will be assessed using the validated Generalized Anxiety Disorder-7 questionnaire. Scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity and worse psychological outcomes.
Measured: Baseline through 24 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2026
- Study start15 Jul 2026
- Primary completion31 Dec 2028 (estimated)
- Study completion30 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Psychological StressStudies of the same condition, open and under way.
- More trials run by Truway Health, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,500 participants (estimated)
- Target duration
- 24 Months
Sponsor and investigators
- Lead sponsor
- Truway Health, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gavin C Solomon, Investigator, Principal investigator, Truway Health, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07622589
- Sponsor's protocol ID
- NFHST-2026-001
- Other IDs
- Sponsor Protocol Number
- Acronym
- NFHST
- Status last verified
- Aug 2026
- First submitted
- 15 May 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Individual participant data (IPD) collected during this study may be shared with qualified researchers, academic institutions, public health entities, and collaborative research organizations following de-identification and in accordance with applicable privacy, ethical, regulatory, and institutional review board requirements. Shared datasets may include: wearable physiologic monitoring data, heart rate variability measurements, sleep monitoring data, behavioral analytics, psychometric assessment results, inflammatory biomarker datasets, and associated digital biomarker outputs. Data sharing may support future research involving: stress physiology, cardiovascular health, behavioral medicine, artificial intelligence-assisted predictive analytics, digital biomarker development, decentralized clinical research, neuroeconomics, and public health forecasting systems. Supporting documents that may be shared include: study protocol, statistical analysis plan, informed consent templates,
Publications
Xiao Y. Bone tissue engineering for dentistry and orthopaedics. Biomed Res Int. 2014;2014:241067. doi: 10.1155/2014/241067. Epub 2014 Nov 26. No abstract available.
PubMed 25525594Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607-28. doi: 10.1146/annurev.clinpsy.1.102803.144141.
PubMed 17716101Eitan R, Shamir RR, Linetsky E, Rosenbluh O, Moshel S, Ben-Hur T, Bergman H, Israel Z. Asymmetric right/left encoding of emotions in the human subthalamic nucleus. Front Syst Neurosci. 2013 Oct 29;7:69. doi: 10.3389/fnsys.2013.00069. eCollection 2013.
PubMed 24194703McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu Rev Med. 2011;62:431-45. doi: 10.1146/annurev-med-052209-100430.
PubMed 20707675Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017.
PubMed 29034226Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA. 2007 Oct 10;298(14):1685-7. doi: 10.1001/jama.298.14.1685. No abstract available.
PubMed 17925521Steptoe A, Kivimaki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012 Apr 3;9(6):360-70. doi: 10.1038/nrcardio.2012.45.
PubMed 22473079Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig. 2018 Mar;15(3):235-245. doi: 10.30773/pi.2017.08.17. Epub 2018 Feb 28.
PubMed 29486547Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, Meldrum DR. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol. 2007 Jan;42(1):142-9. doi: 10.1016/j.yjmcc.2006.09.016. Epub 2006 Oct 30.
PubMed 17070836McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998 Jan 15;338(3):171-9. doi: 10.1056/NEJM199801153380307. No abstract available.
PubMed 9428819Peters A, McEwen BS. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015 Sep;56:139-50. doi: 10.1016/j.neubiorev.2015.07.001. Epub 2015 Jul 3.
PubMed 26148986Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007 Feb;74(2):224-42. doi: 10.1016/j.biopsycho.2005.11.013. Epub 2006 Dec 19.
PubMed 17182165Solomon G. NeuroFinance Human Stress Trial: AI-Driven Physiologic and Behavioral Response Modeling During Financial Market Volatility and Information-Driven Stress Exposure. Truway Health, Inc. Protocol NFHST-2026-001. New York, NY; 2026.
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)
- ClinicalTrials.gov ID
- NCT07622589
- Acronym / sponsor ID
- NFHST / NFHST-2026-001
- Conditions
- Psychological Stress, Anxiety, Emotional Stress, Autonomic Nervous System Dysfunction, Sleep Disturbance, Insomnia
- Keywords
- NeuroFinance, Financial Stress Medicine, Wearable Biosensors, Artificial Intelligence, Machine Learning, Digital Biomarkers, Heart Rate Variability, Sleep Monitoring
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 2,500 participants (estimated)
- Lead sponsor
- Truway Health, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Jul 2026 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 30 Jun 2029 (estimated)
- First posted
- 3 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
Detailed description
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a prospective, decentralized observational study designed to evaluate physiologic and behavioral responses associated with exposure to financial market volatility, economic uncertainty, and digitally mediated informational stress environments.
Participants will undergo remote monitoring using commercially available wearable biosensor technologies and digital health platforms. Data collection may include continuous or intermittent monitoring of:
Heart rate variability (HRV) Resting heart rate Sleep duration and sleep efficiency Blood pressure measurements Physical activity metrics Galvanic skin response Voice-based behavioral analytics Optional electrocardiographic monitoring
Environmental and informational exposure datasets may include:
Financial market volatility indices News sentiment datasets Social media exposure metrics Economic uncertainty indicators Behavioral interaction telemetry
Artificial intelligence and machine learning systems may be used for exploratory correlation analyses between physiologic biomarkers and external informational stressors.
No investigational drug or invasive intervention will be administered as part of this observational study.
Optional biologic sampling may include saliva-based inflammatory biomarker collection and participant-reported psychometric assessments.
Primary analyses will evaluate longitudinal changes in physiologic stress-related biomarkers during periods of elevated informational or financial stress exposure.
Secondary analyses will evaluate associations between physiologic variability, behavioral adaptation metrics, sleep disruption, and cognitive performance measures.
The study is intended to support development of digital biomarker methodologies and decentralized monitoring frameworks for stress-related physiologic research.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 24 Months
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Retail Investors / Active Traders Cohort | – | Device: Wearable Physiologic Monitoring PlatformParticipants actively engaged in retail equity, options, futures, cryptocurrency, or other financial trading activities who are exposed to frequent market volatility and information-driven financial stress environments. |
| Financial Professionals Cohort | – | Device: Wearable Physiologic Monitoring PlatformParticipants employed in financial services, institutional trading, investment banking, hedge funds, private equity, fintech, wealth management, or related high-stress financial occupations. |
| General Population Control Cohort | – | Device: Wearable Physiologic Monitoring PlatformParticipants from the general population with varying levels of financial market exposure serving as a comparative baseline cohort for physiologic and behavioral stress-response analysis. |
| High Digital Media Exposure Cohort | – | Device: Wearable Physiologic Monitoring PlatformParticipants with elevated exposure to financial news, algorithmic media feeds, social media platforms, and information-intensive digital environments associated with financial and geopolitical stress signaling. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of adult participants exposed to varying levels of financial market activity, economic stress environments, occupational stress, and digital media exposure. Participants may include retail investors, financial professionals, active traders, technology workers, digitally connected individuals, and members of the general population. The study is designed to evaluate physiologic, behavioral, cardiovascular, autonomic nervous system, and sleep-related responses to financial and informational stress environments using wearable biosensors, digital health technologies, and artificial intelligence-assisted analytics platforms.
Key inclusion criteria (8 listed)
- Adults age 18 years and older.
- Ability to provide informed consent.
- Willingness and ability to comply with study procedures and remote monitoring requirements.
- Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation.
- Willingness to utilize wearable physiologic monitoring technologies during the study period.
Key exclusion criteria (6 listed)
- Individuals unable or unwilling to provide informed consent.
- Individuals unable to comply with remote monitoring procedures or wearable device usage requirements.
- Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity.
- Current incarceration or institutionalization limiting voluntary participation.
- Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wearable Physiologic Monitoring PlatformCommercially available wearable physiologic monitoring devices and digital health technologies will be used to collect continuous or intermittent biometric, cardiovascular, autonomic nervous system, behavioral, and sleep-related data during exposure to financial market volatility, economic uncertainty, and information-driven stress environments. Monitoring technologies may include: wearable ECG devices, heart rate variability (HRV) monitors, blood pressure monitoring systems, sleep tracking devices, galvanic skin response sensors, activity monitoring wearables, voice analysis systems, and optional EEG-enabled wearable technologies. Data generated from these systems will be integrated with artificial intelligence and machine learning-based analytics platforms for evaluation of physiologic stress responses and digital biomarker forecasting. | Device | Financial Professionals Cohort, General Population Control Cohort, High Digital Media Exposure Cohort, Retail Investors / Active Traders Cohort |
Primary outcome
Change in Heart Rate Variability (HRV) During Financial Stress Exposure
Time frame: Baseline through 24 Months
Heart rate variability will be measured using wearable electrocardiographic or photoplethysmographic monitoring devices. HRV will be quantified as the root mean square of successive differences (RMSSD) in milliseconds. Higher RMSSD values generally indicate improved autonomic nervous system flexibility and lower physiologic stress burden.
Change in Sleep Duration
Time frame: Baseline through 24 Months
Sleep duration will be measured in hours per night using wearable sleep monitoring devices.
Change in Resting Heart Rate
Time frame: Baseline through 24 Months
Resting heart rate will be measured in beats per minute using wearable biosensor devices.
Change in Perceived Stress Scale-10 (PSS-10) Total Score
Time frame: Baseline through 24 Months
Perceived stress will be assessed using the validated 10-item Perceived Stress Scale-10 questionnaire. Scores range from 0 to 40, with higher scores indicating greater perceived psychological stress and worse stress-related outcomes.
3 secondary outcomes
Change in Sleep Efficiency
Time frame: Baseline through 24 Months
Change in Galvanic Skin Response (GSR) Measurements
Time frame: Baseline through 24 Months
Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score
Time frame: Baseline through 24 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 25525594Xiao Y. Bone tissue engineering for dentistry and orthopaedics. Biomed Res Int. 2014;2014:241067. doi: 10.1155/2014/241067. Epub 2014 Nov 26. No abstract available.
- Background: PubMed 17716101Schneiderman N, Ironson G, Siegel SD. Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2005;1:607-28. doi: 10.1146/annurev.clinpsy.1.102803.144141.
- Background: PubMed 24194703Eitan R, Shamir RR, Linetsky E, Rosenbluh O, Moshel S, Ben-Hur T, Bergman H, Israel Z. Asymmetric right/left encoding of emotions in the human subthalamic nucleus. Front Syst Neurosci. 2013 Oct 29;7:69. doi: 10.3389/fnsys.2013.00069. eCollection 2013.
- Background: PubMed 20707675McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu Rev Med. 2011;62:431-45. doi: 10.1146/annurev-med-052209-100430.
- Background: PubMed 29034226Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017.
- Background: PubMed 17925521Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA. 2007 Oct 10;298(14):1685-7. doi: 10.1001/jama.298.14.1685. No abstract available.
- Background: PubMed 22473079Steptoe A, Kivimaki M. Stress and cardiovascular disease. Nat Rev Cardiol. 2012 Apr 3;9(6):360-70. doi: 10.1038/nrcardio.2012.45.
- Background: PubMed 29486547Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig. 2018 Mar;15(3):235-245. doi: 10.30773/pi.2017.08.17. Epub 2018 Feb 28.
- Background: PubMed 17070836Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, Meldrum DR. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). J Mol Cell Cardiol. 2007 Jan;42(1):142-9. doi: 10.1016/j.yjmcc.2006.09.016. Epub 2006 Oct 30.
- Background: PubMed 9428819McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998 Jan 15;338(3):171-9. doi: 10.1056/NEJM199801153380307. No abstract available.
- Background: PubMed 26148986Peters A, McEwen BS. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015 Sep;56:139-50. doi: 10.1016/j.neubiorev.2015.07.001. Epub 2015 Jul 3.
- Background: PubMed 17182165Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol. 2007 Feb;74(2):224-42. doi: 10.1016/j.biopsycho.2005.11.013. Epub 2006 Dec 19.
- Official study sponsor and clinical research information portal for the NeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST-2026-001), including protocol updates, recruitment information, and data sharing policies.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) collected during this study may be shared with qualified researchers, academic institutions, public health entities, and collaborative research organizations following de-identification and in accordance with applicable privacy, ethical, regulatory, and institutional review board requirements. Shared datasets may include: wearable physiologic monitoring data, heart rate variability measurements, sleep monitoring data, behavioral analytics, psychometric assessment results, inflammatory biomarker datasets, and associated digital biomarker outputs. Data sharing may support future research involving: stress physiology, cardiovascular health, behavioral medicine, artificial intelligence-assisted predictive analytics, digital biomarker development, decentralized clinical research, neuroeconomics, and public health forecasting systems. Supporting documents that may be shared include: study protocol, statistical analysis plan, informed consent templates,
Related trials for Psychological Stress
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Not yet recruiting
Acute Effects of Mat Pilates on Blood Pressure Response to Mental Stress in Higher Education Teachers
Behavior
Not yet recruiting
Financial Tools Access and Navigation (FinTAN)
Serious Mental Illness, Financial Hardship
Recruiting
Neurobehavioral Changes Following Spaceflight Stressors
Stressor, Individual, Alcohol Impairment
Not yet recruiting
Meditation Apps for Stress Management in Black Women
Psychological Stress
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gavin C Solomon, Investigator principal investigator
Truway Health, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psychological Stress and Anxiety, run by Truway Health, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Heart Rate Variability (HRV) During Financial Stress Exposure (time frame: Baseline through 24 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07622589, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.